Description
To accelerate the screening and validation of therapeutic drugs to treat COVID-19, Project Exhale will develop two critical new media products and associated protocols to culture human alveolar cells in 2D and 3D.
Amendment chain · 3 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $500,000 at start, $500,000 after amendment #4 (+$0).
- #12020-09-03$500,000
- #32020-12-15$467,000-$33,000
- #42021-09-27$500,000+$33,000
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2020-09-03 | $500,000 | — | To accelerate the screening and validation of therapeutic drugs to treat COVID-19, Project Exhale will develop… |
| #3 amendment | 2020-12-15 | $467,000 | −$33,000 | To accelerate the screening and validation of therapeutic drugs to treat COVID-19, Project Exhale will develop… |
| #4 amendment | 2021-09-27 | $500,000 | +$33,000 | To accelerate the screening and validation of therapeutic drugs to treat COVID-19, Project Exhale will develop… |
Related records · 10
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 135714426)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 033-2025-2026-Q4-515888 | Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada · Life Sciences Fund Contributions | $2,829,286 | FY2026 |
| 033-2024-2025-Q4-819532 | Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada · SIF Stream2- Growth | $49,900,000 | FY2025 |
| GC-WD-DEO-2019-2020-Q2-24 | Western Economic Diversification Canada | Diversification de l'économie de l'Ouest Canada · Regional Economic Growth through Innovation | $5,000,000 | FY2020 |
| 033-2017-2018-Q4-810905 | Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada · SIF Stream3- Attraction | $22,500,000 | FY2018 |
| GC-WD-DEO-2020-2021-Q1-787 | Western Economic Diversification Canada | Diversification de l'économie de l'Ouest Canada · Western Diversification Program | $946,560 | FY2015 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q2-952647 · retrieved 2026-11-12.